XBI is trading -3.06% at $146.76 on October 13, 2026, amid a biotech-sector pullback, though coverage identifies no clear single catalyst. - Momentum names are cooling. - Industry coverage cites cautious investor sentiment, rising interest rates, disappointing clinical readouts, and reduced public-company acquisition activity as broader sector pressures—not confirmed direct causes of this move.